Pozelimab

About Regeneron

Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.

About Regeneron Pharmaceuticals

Regeneron is a premier biotechnology company with a mission to translate groundbreaking science into life-changing medicines for patients. Its achievements are anchored by its proprietary VelociSuite® technology platforms, which have enabled the development of a robust commercial portfolio and one of the industry's deepest pipelines. The company's strategy combines sustained internal R&D investment with selective, high-value collaborations, all supported by a fully integrated model from discovery to global commercialization.

Therapeutic Areas

Other Complement 3 Glomerulopathy (C3G) Drugs